Popular US remedy recalled over ‘life-threatening fungi' with kids most at risk
Church & Dwight Co, Inc, announced on Friday it is recalling its Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs and Orajel Baby Teething Swabs on Friday 'due to potential microbial contamination identified as fungi in cotton swab components'.
The swabs that are contaminated 'can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries', stated the announcement shared by the country's agency protecting public health.
All lots of the three products are under the recall.
Zicam Cold Remedy Nasal Swabs, designed to shorten the common cold, have the UPC number 732216301205. Zicam Nasal AllClear Swabs, meant for cleansing, were discontinued in December 2024 and have the UPC number 732216301656.
Orajel Baby Teething Swabs, designed to soothe discomfort from teething, have the UPC number 310310400002.
They were distributed nationwide and in Puerto Rico.
Customers should stop using the swabs immediately and contact the company for a full refund. More Trending
There have not been any reports of illness from the swabs, but any concerns should be flagged to the US Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program.
'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions,' stated the notice from the FDA.
Church & Dwight describes itself as a $4.9billion 'leading manufacturer of consumer household and personal care products' based in Ewing, New Jersey.
It comes a few months after Ascent Consumer Products Inc recalled a lot of its SinuCleanse Soft Tip Squeeze Bottle Nasal Wash System nationwide due to tests confirming microbial contamination with Staphylococcus aureus (S. aureus). That bacteria can also cause users with nasal mucosa inflammation or injuries to have blood infections.
Get in touch with our news team by emailing us at webnews@metro.co.uk.
For more stories like this, check our news page.
MORE: Costco and Amazon fitness product sold almost 4,000,000 times recalled over broken bones
MORE: Mums 'in love triangle' fought in school playground in front of children
MORE: Popular clothing retailer to close almost 200 more stores in 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
10 hours ago
- BBC News
Canterbury Christ Church University launches midwifery course
A Kent university is launching a new midwifery degree which aims to incorporate artificial intelligence and teaching about healthcare Christ Church University (CCCU) says its new course will "ensure that our students are well prepared to navigate the complexities of modern maternity care" when it starts in new course comes after the Nursing and Midwifery Council, which has approved it, withdrew accreditation for a previous CCCU midwifery course in Paul Driscoll-Evans, dean of the university's midwifery school, said it had "worked closely with health leaders across Kent, Medway and at national level" to design the course. "Our new curriculum is built on the principles of innovation, inclusivity, excellence and sustainability, ensuring that our students are well prepared to navigate the complexities of modern maternity care."In May 2023, the Nursing and Midwifery Council highlighted concerns that students were not gaining the expertise needed to deliver safe, effective and kind to the university, the new course will incorporate new technologies including AI and virtual healthcare to prepare prospective midwives for future advances in course will be delivered by the university with input from Kent healthcare services including NHS Kent and Medway, as well as maternity service on the course will also teach about how race, gender and other identities can affect people's experience of course will take on its first cohort of 25 students at the university's Canterbury Campus this year, with another cohort at its Medway campus launching in Fox-Collins, director for maternity, neonatal and women's health services at NHS Kent and Medway, said: "Giving people who are passionate about the midwifery profession the opportunity to undertake their training in the maternity services across Kent and Medway will enrich our workplaces and improve our services further."
Reuters
21 hours ago
- Reuters
Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH
Aug 15 (Reuters) - Novo Nordisk ( opens new tab said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver condition known as metabolic dysfunction-associated steatohepatitis. The decision makes Wegovy the first GLP-1 class therapy cleared for MASH, a progressive liver condition that affects around 5% of adults in the U.S., according to the American Liver Foundation. The approval is for use alongside a reduced-calorie diet and increased physical activity. The FDA's approval was based on part 1 of a two-part study that showed Wegovy helped more patients with MASH and liver scarring improve the organ's condition, compared to a placebo. At 72 weeks, nearly 37% of patients on Wegovy saw an improvement in liver fibrosis, compared to 22.4% on placebo. Nearly 63% of those on Wegovy had their liver inflammation resolved, versus 34.3% for placebo. No worsening of the disease was seen in these patients. Accelerated approvals allow the agency to move therapies that target serious and life-threatening conditions to the market more quickly. However, such approvals have been criticized because some drugs have later been proven to be ineffective.
The Independent
a day ago
- The Independent
What to know about new flu vaccine nasal spray
Eligible adults in 34 states can now order the FluMist Home nasal spray flu vaccine online for the first time, allowing for at-home administration. Previously only available at pharmacies or doctors' offices, the vaccine can be ordered via providing a more convenient option for flu protection. FluMist Home is suitable for self-administration by individuals aged 18 to 49, and can also be given to children and teens aged two to 17. The nasal spray, approved by the FDA for at-home use last September, should be stored in a refrigerator and is typically free with insurance, though an $8.99 shipping and processing fee applies. This initiative aims to improve accessibility and convenience for flu vaccination, particularly following the worst flu season in 15 years and declining vaccination rates.
